-
IKT Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Inhibikase Therapeutics (IKT)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 913.42 k | 913.42 k | 913.42 k | 913.42 k | 913.42 k | 913.42 k |
Cash burn (monthly) | 724.35 k | 1.16 mm | 1.94 mm | 1.67 mm | 1.63 mm | 1.44 mm |
Cash used (since last report) | 2.65 mm | 4.26 mm | 7.11 mm | 6.12 mm | 5.96 mm | 5.26 mm |
Cash remaining | -1.74 mm | -3.34 mm | -6.20 mm | -5.21 mm | -5.04 mm | -4.35 mm |
Runway (months of cash) | -2.4 | -2.9 | -3.2 | -3.1 | -3.1 | -3.0 |
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 3 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 75.82 mm |
Total shares | 1.40 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
FiveT Investment Management | 1.34 mm | $971.00 k |
Geode Capital Management | 37.33 k | $48.93 mm |
Renaissance Technologies | 20.82 k | $25.20 mm |
Mather | 334.00 | $721.00 k |
Proequities | 0.00 | $0.00 |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Jan 25 | Dennis N Berman | Stock Option Common Stock | Grant | Acquire A | No | No | 1.58 | 316,647 | 500.30 k | 316,647 |
3 Jan 25 | Dennis N Berman | Stock Option Common Stock | Grant | Acquire A | No | No | 1.45 | 172,191 | 249.68 k | 172,191 |
3 Jan 25 | Dennis N Berman | Stock Option Common Stock | Grant | Acquire A | No | No | 1.26 | 344,452 | 434.01 k | 344,452 |
3 Jan 25 | Freeman Roy Lester | Stock Option Common Stock | Grant | Acquire A | No | No | 1.58 | 316,647 | 500.30 k | 316,647 |
3 Jan 25 | Freeman Roy Lester | Stock Option Common Stock | Grant | Acquire A | No | No | 1.45 | 172,191 | 249.68 k | 172,191 |
3 Jan 25 | Freeman Roy Lester | Stock Option Common Stock | Grant | Acquire A | No | No | 1.26 | 344,452 | 434.01 k | 344,452 |
3 Jan 25 | Garth Lees-Rolfe | Stock Option Common Stock | Grant | Acquire A | No | No | 1.58 | 432,853 | 683.91 k | 432,853 |
3 Jan 25 | Garth Lees-Rolfe | Stock Option Common Stock | Grant | Acquire A | No | No | 1.45 | 235,383 | 341.31 k | 235,383 |
3 Jan 25 | Garth Lees-Rolfe | Stock Option Common Stock | Grant | Acquire A | No | No | 1.26 | 470,861 | 593.28 k | 470,861 |
3 Jan 25 | Milton H. Werner | Stock Option Common Stock | Grant | Acquire A | No | No | 1.58 | 4,059,744 | 6.41 mm | 4,059,744 |